Supernus Pharmaceuticals ... (SUPN)
NASDAQ: SUPN
· Real-Time Price · USD
31.68
0.00 (0.00%)
At close: May 30, 2025, 3:59 PM
31.70
0.06%
After-hours: May 30, 2025, 04:37 PM EDT
0.00% (1D)
| Bid | 30.08 |
| Market Cap | 1.77B |
| Revenue (ttm) | 668M |
| Net Income (ttm) | 61.91M |
| EPS (ttm) | 1.11 |
| PE Ratio (ttm) | 28.54 |
| Forward PE | 12.66 |
| Analyst | Hold |
| Ask | 33.78 |
| Volume | 532,140 |
| Avg. Volume (20D) | 558,012 |
| Open | 31.61 |
| Previous Close | 31.68 |
| Day's Range | 31.43 - 31.90 |
| 52-Week Range | 25.53 - 40.28 |
| Beta | 0.74 |
About SUPN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SUPN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SUPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-15.67%
Supernus Pharmaceuticals shares are trading lower ...
Unlock content with
Pro Subscription
3 months ago
+1.64%
Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.
3 weeks ago · seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executiv...
